Skip to main
ADPT

Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Adaptive Biotechnologies (ADPT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Adaptive Biotechnologies is on a positive trajectory, with FDA approval for their diagnostic assay, strategic investments and partnerships, and strong financial performance. Their focus on separating their businesses and expanding in the MRD market, along with their well-validated immune profiling platform, make them a solid investment opportunity for the future.

Bears say

Adaptive Biotechnologies is a promising company in the field of immune-driven medicine, but potential risks make us have a negative outlook on its stock. While gaining FDA approval and expanding into different markets could boost revenue, the stock is currently overvalued and faces risks such as shifts in research and development budgets, dependencies on volatile emerging markets, and potential hurdles in the regulatory process. Additionally, the company plans to separate its Immune Medicine business from its core MRD business, but there is no guarantee this will occur as planned. Financially, the company has strong revenue growth, but the stock is trading at a premium multiple compared to similar companies in the industry.

Adaptive Biotechnologies (ADPT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adaptive Biotechnologies (ADPT) Forecast

Analysts have given Adaptive Biotechnologies (ADPT) a Buy based on their latest research and market trends.

According to 6 analysts, Adaptive Biotechnologies (ADPT) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adaptive Biotechnologies (ADPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.